CompletedPhase 3NCT02970162
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Studying Lambert-Eaton myasthenic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Catalyst Pharmaceuticals, Inc.
- Principal Investigator
- Perry Shieh, MD, PhDUniversity of California, Los Angeles
- Intervention
- Amifampridine Phosphate(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2017
Study locations (1)
- UCLA, Los Angeles, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02970162 on ClinicalTrials.gov